PROF
NASDAQProfound Medical
$6.91
+1.23 (+21.65%)
2026-10-08 00:00
Healthcare
Medical Devices
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$213.7M
P/E Ratio
N/A
52W Low
52W High
$4.80
$8.95
Volume
3.0M
Analyst Rating
Hold
Target: $11
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $11
Avg: $11
High: $12
About Profound Medical
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue....
Employees
162
Website
profoundmedical.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $16.4M | -256.3% | -$43.3M | -$38.7M |
| 2024 | $10.2M | -309.6% | -$26.5M | -$23.5M |
| 2023 | $7.2M | -397.5% | -$28.6M | -$22.6M |
| 2022 | $6.7M | -480.9% | -$28.7M | -$25.8M |
| 2021 | $6.9M | -440.7% | -$30.7M | -$21.8M |
| 2026 Q2 | $2.5M | -445.7% | -$9.5M | -$11.3M |
| 2026 Q1 | $5.3M | -150.3% | -$7.0M | -$8.6M |
| 2025 Q4 | $6.0M | -123.3% | -$8.2M | -$6.5M |
| 2025 Q3 | $5.3M | -168.5% | -$8.0M | -$9.6M |
| 2025 Q2 | $2.2M | -624.4% | -$15.7M | -$13.7M |
| 2025 Q1 | $2.6M | -426.0% | -$10.7M | -$8.3M |
| 2024 Q4 | $4.1M | -199.8% | -$5.3M | -$5.6M |
| 2024 Q3 | $2.8M | -369.0% | -$9.4M | -$6.8M |